Table 1

Patient characteristics

Patients (n = 71)
Baseline  
 Male/female, n 30/41 
 Median age, y (range) 69 (59-83) 
 ECOG PS 0/1/2/3, n 21/44/5/1 
 Median CIRS (range) 6 (0-16) 
 CIRS-G >4, n (%)* 54 (77%) 
 CNS disease, n 
 Median WBC, 109/L (range) 12.4 (0.8-348.3) 
 WBC ≥30 × 109/L, n (%) 27 (38) 
Karyotype Successful (n = 64) 
 Ph on karyotype analysis 61 (95%) 
 Presence of ACAs, n (%) 48 (79%) 
 Supernumerary Ph, n (%) 19 (31%) 
  Hyperdiploidy 47-50, n (%) 17 (28%) 
  Deletion 9p, n (%) 15 (25%) 
  Monosomy 7 or deletion 7p, n (%) 12 (20%) 
Molecular biology, n  
 Bcr subtype (m/M/both) 54/17/0 
Patients (n = 71)
Baseline  
 Male/female, n 30/41 
 Median age, y (range) 69 (59-83) 
 ECOG PS 0/1/2/3, n 21/44/5/1 
 Median CIRS (range) 6 (0-16) 
 CIRS-G >4, n (%)* 54 (77%) 
 CNS disease, n 
 Median WBC, 109/L (range) 12.4 (0.8-348.3) 
 WBC ≥30 × 109/L, n (%) 27 (38) 
Karyotype Successful (n = 64) 
 Ph on karyotype analysis 61 (95%) 
 Presence of ACAs, n (%) 48 (79%) 
 Supernumerary Ph, n (%) 19 (31%) 
  Hyperdiploidy 47-50, n (%) 17 (28%) 
  Deletion 9p, n (%) 15 (25%) 
  Monosomy 7 or deletion 7p, n (%) 12 (20%) 
Molecular biology, n  
 Bcr subtype (m/M/both) 54/17/0 

ACAs, additional cytogenetic abnormalities; Bcr, BCR-ABL breakpoint; PS, performance status; CIRS, cumulative illness rating scale; m, minor breakpoint; M, major breakpoint; WBC, white blood cell count.

*

n = 70.

Only ACAs present in at least 20% of Ph+ cases are listed; ACAs were often combined.

Close Modal

or Create an Account

Close Modal
Close Modal